Dosing & Administration

How to administer Adequan® Canine to proactively treat canine osteoarthritis (OA) disease, not just the clinical signs.1

At early signs of OA or degenerative joint disease (DJD), veterinarians can prescribe Adequan® Canine (polysulfated glycosaminoglycan) at the approved dose to help slow the disease progression with the expectation of achieving the same results shown in clinical studies.1 After the initial series, veterinarians and owners should work together to keep monitoring the dog’s joint health and mobility. Repeat the dosing regimen as needed upon recurrence of clinical signs.

Adequan Canine Veterinarian dog clinic
Adequan Canine Start With It
  • Use Adequan® Canine early, at the first clinical signs of OA before it progresses, and cartilage is irreversibly damaged.1
  • Administer twice weekly for up to 4 weeks (maximum of 8 injections) at approved dosage of 2 mg/lb body weight (0.02 mL/lb or 1 mL/50 lb) by intramuscular (IM) injection only.2 Do not exceed the recommended dose or therapeutic regimen. Do not mix Adequan® Canine with other drugs or solvents. Use within 28 days of first puncture and puncture a maximum of 10 times.
  • You may see signs of improvement within one month.1
Adequan Canine Stay With It
  • Continue to prescribe Adequan® Canine as needed to help slow down the clock of arthritis.

How Adequan® Canine (polysulfated glycosaminoglycan) can help extend a dog’s mobility over a lifetime.

Adequan Canine lifetime of mobility chart

IM injection provides fast relief and reliable delivery to synovial joints.

Within 2 hours, Adequan® Canine reaches all synovial joints to begin helping to restore joint tissues that are damaged or inflamed — and lasts
for approximately 3 days.1

The specific mechanism of action of Adequan® in canine joints is not known.

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)
INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information.
1. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 FOI Summary, 1997.
2. Adequan® Canine Package Insert, Rev. 1/19

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

CANINE VETERINARY
PROFESSIONAL
DOG OWNER
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands